Kingdon Capital Management’s AbbVie ABBV Stock Holding History

Kingdon Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-99,200	Closed	-$13.4M	–	83
2021 Q4	$13.4M	Buy	+99,200	New	+$11.7M	1.54%	21

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Kingdon Capital Management's ABBV Position: Q1 2022 in Review

Kingdon Capital Management sold out of AbbVie (ABBV) in Q1 2022, closing a stake of 99,200 shares — an estimated $13.4M sold.

Kingdon Capital Management first reported a position in ABBV in Q4 2021 and held it in 1 quarter. The position peaked at $13.4M in Q4 2021. 3,051 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

Kingdon Capital Management reported no remaining AbbVie position as of Q1 2022 after selling out during the quarter.
Kingdon Capital Management sold 99,200 AbbVie shares in Q1 2022, an estimated $13.4M.
Kingdon Capital Management first reported a position in AbbVie in Q4 2021 and held it in 1 quarter.
Kingdon Capital Management's AbbVie position peaked at $13.4M in Q4 2021.
3,051 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Kingdon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.